Celecoxib significantly suppressed HT29 cell CD133 expression through AKT inhibition, and this was faithfully represented by reduced cellular 89Zr-CD133 IgG binding in vitro and tumor 89Zr-CD133 IgG uptake in vivo. This evidence concerns the gene AKT1 and neoplasm.